Molecular Diagnostics Market Projected to Reach $30.74 Billion by 2030, Driven by Precision Medicine and Early Disease Detection
核心洞察
The global molecular diagnostics market is projected to grow from USD 19.48 billion in 2025 to USD 30.74 billion by 2030, at a CAGR of 9.6%, according to MarketsandMarkets.
PCR and real-time PCR technologies dominate the market with a 42.54% revenue share, while sequencing-based testing is the fastest-growing segment due to personalized medicine adoption.
North America leads the global market with a 38.49% share, while Asia Pacific is the fastest-growing region with an estimated CAGR of 24.45% through 2035.
The global molecular diagnostics market is on a robust growth trajectory, with MarketsandMarkets projecting expansion from USD 19.48 billion in 2025 to USD 30.74 billion by 2030, reflecting a compound annual growth rate (CAGR) of 9.6%. This growth is fueled by the accelerating shift toward precision medicine, rising demand for early disease detection, and continuous technological innovation across PCR, next-generation sequencing (NGS), and in situ hybridization (ISH) platforms.
A separate analysis by SNS Insider values the nucleic acid testing market at USD 4.52 billion in 2025, with projections reaching USD 8.42 billion by 2035 at a CAGR of 6.57%. The U.S. market alone is expected to grow from approximately USD 1.40 billion in 2025 to USD 2.55 billion by 2035, while Europe is forecast to expand from USD 1.31 billion to USD 2.39 billion over the same period.
Technology Landscape: PCR Dominates, Sequencing Surges
Polymerase chain reaction (PCR) and real-time PCR remain the cornerstone of molecular diagnostics, commanding a 42.54% revenue share of the nucleic acid testing market in 2025. According to SNS Insider, this dominance is attributed to high sensitivity, fast turnaround times, and widespread clinical utility across infectious disease testing, blood screening, and genetic analysis.
However, sequencing-based testing represents the fastest-growing technology segment, driven by increased adoption of personalized medicine and genomic profiling. Breakthroughs in NGS, combined with advancements in automation and software-driven analytics, are transforming laboratory workflows and enabling tailored therapies based on genetic and molecular profiles.
Test Type and Sample Dynamics
Lab-based tests continue to dominate the market, accounting for a significant share in 2024. Centralized laboratories equipped with high-throughput platforms support large patient volumes and offer superior accuracy, sensitivity, and comprehensive assay menus. Ongoing advancements in automation and multiplexing technologies further reinforce their market leadership.
Among sample types, blood, serum, and plasma are projected to register the highest CAGR during the forecast period. These sample types are widely preferred due to their reliability, ease of collection, and compatibility with multiple molecular testing platforms. Innovations in liquid biopsy and non-invasive diagnostic techniques are accelerating adoption, particularly in oncology and genetic testing. Blood samples alone accounted for a 37.45% market share in 2025, according to SNS Insider data.
Application Areas: Infectious Disease Leads, Oncology Rising
Infectious disease diagnostics led the nucleic acid testing market with a 39.44% share in 2025, reflecting the rising global burden of viral and bacterial infections and the critical need for early and accurate detection. The oncology testing category is the fastest-growing application segment, driven by increasing use of molecular testing for cancer diagnosis, biomarker detection, and treatment selection.
End-User Landscape
Hospitals and diagnostic laboratories held the forefront of the market in 2025 with a 43.59% share, benefiting from extensive testing volumes, improved laboratory infrastructure, and integration of molecular diagnostic techniques into daily healthcare services. The pharmaceutical and biotechnology companies segment is the fastest-growing end-user category, fueled by increased investment in drug discovery, biomarker identification, genetic research, and personalized medicine initiatives.
Regional Outlook: North America Leads, Asia Pacific Accelerates
North America maintains its position as the largest regional market, holding a 38.49% share in 2025. This leadership is supported by advanced healthcare infrastructure, strong adoption of cutting-edge technologies, favorable regulatory frameworks, consistent R&D investments, and well-established reimbursement systems. The U.S. market, valued at approximately USD 1.40 billion in 2025, is expected to reach USD 2.55 billion by 2035, growing at a CAGR of approximately 6.30%.
Europe represents the second-largest market, estimated at USD 1.31 billion in 2025 and projected to reach USD 2.39 billion by 2035 at a CAGR of 6.20%. Countries including Germany, the UK, France, and Italy continue to advance molecular technology adoption through healthcare transformation initiatives, genomics research, and cancer screening programs.
Asia Pacific emerges as the most rapidly developing region, with a CAGR estimated at approximately 24.45% during 2026–2035. Key growth drivers include developing healthcare infrastructure, increased prevalence of infectious diseases, expanding genomics research, higher healthcare spending, and growing implementation of precision medicine across China, India, Japan, and Southeast Asian countries.
Competitive Landscape and Recent Developments
The molecular diagnostics market features a concentrated competitive landscape with leading players including Danaher Corporation (搜索), F. Hoffmann-La Roche Ltd., Hologic, Inc., Illumina, Inc., Abbott (搜索), bioMérieux, Thermo Fisher Scientific Inc. (搜索), QIAGEN N.V. (搜索), Revvity, Inc., Myriad Genetics, Inc., Siemens Healthineers AG (搜索), Becton, Dickinson and Company (BD), Grifols, S.A., QuidelOrtho Corporation, DiaSorin S.p.A., and Exact Sciences Corporation.
In 2026, Thermo Fisher Scientific expanded its molecular diagnostics capabilities through enhanced automated nucleic acid testing workflows and high-throughput laboratory integration platforms designed to support growing infectious disease and genomic testing volumes across North America and Europe. Concurrently, Roche Diagnostics strengthened its molecular testing ecosystem by advancing next-generation multiplex assay development and integrated digital laboratory solutions aimed at improving testing efficiency and reducing turnaround times in clinical laboratories.
The reagents and kits segment dominated the nucleic acid testing market in 2025 with a 46.69% share, driven by high testing volumes and continuous demand for consumables. The software and services segment is the fastest-growing product category, reflecting increasing laboratory digitization, AI-powered workflow automation, and molecular data analytics adoption globally.
Strategic Implications
As healthcare systems worldwide prioritize early diagnosis, precision medicine, and cost efficiency, molecular diagnostics is becoming a strategic investment area. Organizations that align with technological advancements and expand their diagnostic capabilities are positioned to capture growth opportunities and deliver improved patient outcomes. The convergence of AI-enabled molecular testing, decentralized testing solutions, and next-generation nucleic acid testing technologies is expected to shape the future of molecular healthcare.